FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
FDA approves new pain drug Journavx as opioid alternative
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
FDA approves first new non-opioid pain pill in decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
FDA approves first new non-opioid pain pill in 20 years—how it works
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
The Express Tribune16h
FDA approves non-opioid pain medication as new alternative for pain relief
The FDA approves suzetrigine, a non-opioid pain medication, offering a safer alternative to opioids for pain management, ...
Middle East Eye1h
Children with pre-war chronic illnesses are falling through the cracks in Gaza
Six-year-old Hassan Abed Raboh lives with an excruciating bladder condition that 25 operations at Gaza hospitals could not ...
FDA approves new type of non-opioid pain medication in two decades
The FDA has approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin, the first of its kind in 20 years.
btimesonline20h
FDA Greenlights Groundbreaking Pain Medication, But Is It Effective Enough?
The U.S. Food and Drug Administration (FDA) on Thursday approved Journavx, the first new class of pain medication in more ...